Pharma

Taking stock of the drug industry, from the lab to the medicine chest

The capitol at sunrise

Pharmalot

Gilead CEO to testify before a House committee about pricing for its HIV prevention pill

By Ed Silverman

Exclusive

Novartis may be close to settling a kickback case on the eve of a trial

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Biogen reaches deal with U.K. for its SMA drug; did Gilead thwart generic competition to an HIV pill?

By Ed Silverman

advertisement

Consortium Of Hospitals

Pharmalot

Two new ventures strike deals with drug makers to combat generic shortages

By Ed Silverman

Gilead

Pharmalot

Gilead struck anti-competitive deals to bolster profits on an HIV drug, lawsuit says

By Ed Silverman

AbbVie California

Pharmalot

AbbVie settles key patent litigation over Humira, preserving ‘monopoly prices’ in the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: Tariffs on China don’t include medicines; 340B purchases are skyrocketing

By Ed Silverman

advertisement

Cocktail party

Pharmalot

New Jersey amends rules on pharma gifts to doctors and eases restrictions on meals

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: States sue more generic drug makers for price fixing; Sacklers squabble among themselves

By Ed Silverman

Retro television

The Pharmalot View

Grandstanding, not real change: Why drug prices in TV ads will be confusing and irrelevant

By Ed Silverman

Pill assortment

Pharma

States bring new price-fixing suit against generic-drug makers

By Steve LeBlanc and Martin Crutsinger — Associated Press

FDA campus

Politics

FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic

By Nicholas Florko and Ed Silverman

Hires

Pharmalot

Up and down the ladder: the latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Gilead donates Truvada to mixed reactions; Trump gambles in his push for drug importation

By Ed Silverman

Truvada bottle and pills

Pharmalot

Gilead will donate Truvada for HIV prevention, but reaction is mixed

By Ed Silverman

Truvada/PReP

Pharmalot

A generic version of a Gilead HIV pill will arrive sooner than expected, but AIDS activists remain unhappy

By Ed Silverman

Pharmalot

Pharmalittle: Takeda sells $3.8 billion in drugs to pay debts; a caravan heads to Canada for insulin

By Ed Silverman

Pharmalot

Pharma pushes back against setting international standards for drug-pricing transparency

By Ed Silverman

Pharmalot

Pharmalittle: Trump OKs prices in TV drug ads; Allergan CEO says ‘everything is on the table’

By Ed Silverman

Annie Kuster & Nancy Pelosi

Politics

Facing pressure across Washington, drug industry courts pro-business Democrats

By Lev Facher and Nicholas Florko

Pill illo

Pharmalot

Laura Jacobus hopes to provide her newly approved drug at ‘little or no’ cost to patients

By Ed Silverman

Medicine

Pharmalot

California cites Cardinal Health for shipping controlled substances to a dead pharmacist

By Ed Silverman

Subsys 1600 mcg video

Business

Insys jurors horrified at use of rap video to push sales

By Maria Cramer — Boston Globe and Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

By Ed Silverman

Insulin

Pharmalot

Should the U.S. save Medicare money by pegging drug prices to what other countries pay?

By Ed Silverman

Pharmalot

In a crafty move, FDA may have found a way to dampen controversy over a $375,000 rare-disease drug

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer prices new rare disease drug at $225,000; Novartis pushes gene therapy

By Ed Silverman

Richard A. Gonzalez and others testifying

Pharmalot

Most AbbVie shareholders are unfazed that the CEO’s bonus is tied to high prices for Humira

By Ed Silverman

Early warning system

Pharmalot

Which regulator is most likely to issue a safety advisory about a drug risk?

By Ed Silverman

« Previous Page